Thyroid tumors: novel insights from proteomic studies

References

• Liu S, Semenciw R, Ugnat AM, Mao Y. Increasing thyroid cancer incidence in Canada, 1970–1996: time trends and age-period-cohort effects. Br. J. Cancer85(9), 1335–1339 (2001).
   PubMed Web of Science ®Google Scholar
• Farahati J, Geling M, Mäder U et al. Changing trends of incidence and prognosis of thyroid carcinoma in lower Franconia, Germany, from 1981–1995. Thyroid14(2), 141–147 (2004).
   PubMed Web of Science ®Google Scholar
• Eszlinger M, Krohn K, Hauptmann S, Dralle H, Giordano TJ, Paschke R. Perspectives for improved and more accurate classification of thyroid epithelial tumors. J. Clin. Endocrinol. Metab.93(9), 3286–3294 (2008).
   PubMed Web of Science ®Google Scholar
• Gimm O. Thyroid Cancer. Cancer Lett.163(2), 143–156 (2001).
   PubMed Web of Science ®Google Scholar
• Potenza M, Mechanick Ji. Low-risk thyroid carcinoma: when is the treatment worse than the disease? Expert Rev. Endocrinol. Metab.4(1), 5–7 (2009).
   PubMedGoogle Scholar
• Melillo RM, Castellone MD, Guarino V et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J. Clin. Invest.115(4), 1068–1081 (2005).
   PubMed Web of Science ®Google Scholar
• Hunt J. Understanding the genotype of follicular thyroid tumors. Endocr. Pathol.16(4), 311–321 (2005).
   PubMed Web of Science ®Google Scholar
• Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J. Clin. Endocrinol. Metab.83(11), 4116–4122 (1998).
   PubMed Web of Science ®Google Scholar
• Basolo F, Giannini R, Monaco C et al. Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. Am. J. Pathol.160(1), 247–754 (2002).
   PubMed Web of Science ®Google Scholar
• Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF, de Micco C. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J. Clin. Endocrinol. Metab.88(6), 2745–2752 (2003).
   PubMed Web of Science ®Google Scholar
• Castro P, Rebocho AP, Soares RJ et al. PAX8-PPARγ rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab.91(1), 213–220 (2006).
   PubMed Web of Science ®Google Scholar
• Nikiforova MN, Kimura ET, Gandhi M et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab.88(11), 5399–5404 (2003).
   PubMed Web of Science ®Google Scholar
• Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D, Westra WH. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod. Pathol.17(11), 1359–1363 (2004).
   PubMed Web of Science ®Google Scholar
• Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer103(11), 2261–2268 (2005).
   PubMed Web of Science ®Google Scholar
• Damante G, Tell G, Di Lauro R. A unique combination of transcription factors controls differentiation of thyroid cells. Prog. Nucleic Acid Res. Mol. Biol.66, 307–356 (2001).
   PubMedGoogle Scholar
• Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R, Damante G. Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res.54(17), 4744–4749 (1994).
   PubMed Web of Science ®Google Scholar
• Ros P, Rossi DL, Acebrón A, Santisteban P. Thyroid-specific gene expression in the multi-step process of thyroid carcinogenesis. Biochimie81(4), 389–396 (1999).
   PubMed Web of Science ®Google Scholar
• Vasko V, Espinosa AV, Scouten W et al. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc. Natl. Acad. Sci. USA104(8), 2803–2808 (2007).
   PubMed Web of Science ®Google Scholar
• Guarino V, Faviana P, Salvatore G et al. Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J. Clin. Endocrinol. Metab.90(9), 5270–5278 (2005).
   PubMed Web of Science ®Google Scholar
• Fluge Ø, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE. Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid16(2), 161–175 (2006).
   PubMed Web of Science ®Google Scholar
• Puppin C, Fabbro D, Dima M et al. High periostin expression correlates with aggressiveness in papillary thyroid carcinomas. J. Endocrinol.197(2), 401–408 (2008).
   PubMed Web of Science ®Google Scholar
• Barden CB, Shister KW, Zhu B et al. Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin. Cancer Res.9(5), 1792–1800 (2003).
   PubMed Web of Science ®Google Scholar
• Finley DJ, Zhu B, Barden CB, Fahey TJ. Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann. Surg.240(3), 425–436 (2004).
   PubMed Web of Science ®Google Scholar
• Mazzanti C, Zeiger MA, Costouros NG et al. Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res.64(8), 2898–2903 (2004).
   PubMed Web of Science ®Google Scholar
• Weber F, Shen L, Aldred MA et al. Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. J. Clin. Endocrinol. Metab.90(5), 2512–2521 (2005).
   PubMed Web of Science ®Google Scholar
• Fontaine JF, Mirebeau-Prunier D, Franc B et al. Microarray analysis refines classification of non-medullary thyroid tumours of uncertain malignancy. Oncogene27(15), 2228–2236 (2008).
   PubMed Web of Science ®Google Scholar
• Jarzab B, Wiench M, Fujarewicz K et al. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res.65(4), 1587–1597 (2005).
   PubMed Web of Science ®Google Scholar
• Kebebew E, Peng M, Reiff E, McMillan A. Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. Cancer106(12), 2592–2597 (2006).
   PubMed Web of Science ®Google Scholar
• Tian Q, Stepaniants SB, Mao M et al. Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol. Cell. Proteomics3(10), 960–969 (2004).
   PubMed Web of Science ®Google Scholar
• Hanash S. Disease proteomics. Nature422(6928), 226–232 (2003).
   PubMed Web of Science ®Google Scholar
• Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature422(6928), 198–207 (2003).
   PubMed Web of Science ®Google Scholar
• Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J. Physiol.563(1), 23–60 (2005).
   PubMed Web of Science ®Google Scholar
• Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature452(7187), 571–579 (2008).
   PubMed Web of Science ®Google Scholar
• O’Farrell PH. High resolution two-dimensional electrophoresis of proteins. J. Biol. Chem.250(10), 4007–4021 (1975).
   PubMed Web of Science ®Google Scholar
• Bjellqvist B, Ek K, Righetti PG et al. Isoelectric focusing in immobilized pH gradients: principle, methodology and some applications. J. Biochem. Biophys. Methods6(4), 317–339 (1982).
   PubMedGoogle Scholar
• Yates JR, Gilchrist A, Howell KE, Bergeron JJ. Proteomics of organelles and large cellular structures. Nat. Rev. Mol. Cell. Biol.6(9), 702–714 (2005).
   PubMed Web of Science ®Google Scholar
• Everley PA, Zetter BR. Proteomics in tumor progression and metastasis. Ann. NY Acad. Sci.1059, 1–10 (2005).
   PubMed Web of Science ®Google Scholar
• Cho WC. Contribution of oncoproteomics to cancer biomarker discovery. Mol. Cancer6, 25–38 (2007).
   PubMed Web of Science ®Google Scholar
• Verrills NM. Clinical proteomics: present and future prospects. Clin. Biochem. Rev.27(2), 99–116 (2006).
   PubMedGoogle Scholar
• Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics4(12), 3665–3685(2004).
   PubMed Web of Science ®Google Scholar
• Timms JF, Cramer R. Difference gel electrophoresis. Proteomics8(23–24), 4886–4897 (2008).
   PubMed Web of Science ®Google Scholar
• Riederer BM. Non-covalent and covalent protein labeling in two-dimensional gel electrophoresis. J. Proteomics71(2), 231–244 (2008).
   PubMed Web of Science ®Google Scholar
• Seike M, Kondo T, Fujii K et al. Proteomic signatures for histological types of lung cancer. Proteomics5(11), 2939–2948 (2005).
   PubMed Web of Science ®Google Scholar
• Friedman DB, Hill S, Keller JW et al. Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics4(3), 793–811 (2004).
   PubMed Web of Science ®Google Scholar
• Sun W, Xing B, Sun Y et al. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues. Mol. Cell. Proteomics6(10), 1798–1808 (2007).
   PubMed Web of Science ®Google Scholar
• Somiari RI, Sullivan A, Russell S et al. High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast. Proteomics3(10), 1863–1873 (2003).
   PubMed Web of Science ®Google Scholar
• Zhou G, Li H, DeCamp D et al. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol. Cell. Proteomics1(2), 117–124 (2002).
   PubMed Web of Science ®Google Scholar
• Morita A, Miyagi E, Yasumitsu H, Kawasaki H, Hirano H, Hirahara F. Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma. Proteomics6(21), 5880–5890 (2006).
   PubMed Web of Science ®Google Scholar
• Gharbi S, Gaffney P, Yang A et al. Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol. Cell. Proteomics1(2), 91–98 (2002).
   PubMed Web of Science ®Google Scholar
• Han X, Aslanian A, Yates JR. Mass spectrometry for proteomics. Curr. Opin. Chem. Biol.12(5), 483–490 (2008).
   PubMed Web of Science ®Google Scholar
• Lim MS, Elenitoba-Johnson KS. Proteomics in pathology research. Lab. Invest.84(10), 1227–1244 (2004).
   PubMed Web of Science ®Google Scholar
• Palagi PM, Hernandez P, Walther D, Appel RD. Proteome informatics I: bioinformatics tools for processing experimental data. Proteomics6(20), 5435–5444 (2006).
   PubMed Web of Science ®Google Scholar
• Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nat. Biotechnol.21(3), 255–261 (2003).
   PubMed Web of Science ®Google Scholar
• Ong SE, Mann M. Mass spectrometry-based proteomics turns quantitative. Nat. Chem. Biol.1(5), 252–262 (2005).
   PubMed Web of Science ®Google Scholar
• Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol.17(10), 994–999 (1999).
   PubMed Web of Science ®Google Scholar
• Ross PL, Huang YN, Marchese JN et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics3(12), 1154–1169 (2004).
   PubMed Web of Science ®Google Scholar
• Ong SE, Blagoev B, Kratchmarova I et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics1(5), 376–386 (2002).
   PubMed Web of Science ®Google Scholar
• Washburn MP, Wolters D, Yates JR. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol.19(3), 242–247 (2001).
   PubMed Web of Science ®Google Scholar
• Swanson SK, Florens L, Washburn MP. Generation and analysis of multidimensional protein identification technology datasets. Methods Mol. Biol.492, 1–20 (2009).
   PubMedGoogle Scholar
• Hall DA, Ptacek J, Snyder M. Protein microarray technology. Mech. Ageing Dev.128(1), 161–167 (2007).
   PubMed Web of Science ®Google Scholar
• Tang N, Tornatore P, Weinberger SR. Current developments in SELDI affinity technology. Mass Spectrom. Rev.23(1), 34–44 (2004).
   PubMed Web of Science ®Google Scholar
• Xiao Z, Adam BL, Cazares LH et al. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res.61(16), 6029–6033 (2001).
   PubMed Web of Science ®Google Scholar
• Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet359(9306), 572–577 (2002).
   PubMed Web of Science ®Google Scholar
• Villanueva J, Shaffer DR, Philip J et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest.116(1), 271–284 (2006).
   PubMed Web of Science ®Google Scholar
• Weinberger SR, Dalmasso EA, Fung ET. Current achievements using ProteinChip Array technology. Curr. Opin. Chem. Biol.6(1), 86–91 (2002).
   PubMed Web of Science ®Google Scholar
• Caiazzo RJ, Maher AJ, Drummond MP et al. Protein microarrays as an application for disease biomarkers. Proteomics Clin. Appl.2, 138–147 (2009).
   Google Scholar
• Phizicky E, Bastiaens PI, Zhu H, Snyder M, Fields S. Protein analysis on a proteomic scale. Nature422(6928), 208–215 (2003).
   PubMed Web of Science ®Google Scholar
• Liotta LA, Espina V, Mehta AI et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell3(4), 317–325 (2003).
   PubMed Web of Science ®Google Scholar
• Kodadek T. Protein microarrays: prospects and problems. Chem. Biol.8(2), 105–115 (2001).
   PubMed Web of Science ®Google Scholar
• Greenbaum D, Baruch A, Hayrapetian L et al. Chemical approaches for functionally probing the proteome. Mol. Cell. Proteomics1(1), 60–68 (2002).
   PubMed Web of Science ®Google Scholar
• Wilson DS, Nock S. Recent developments in protein microarray technology. Angew. Chem. Int. Ed. Engl.42(5), 494–500 (2003).
   PubMed Web of Science ®Google Scholar
• Seeley EH, Caprioli RM. Molecular imaging of proteins in tissues by mass spectrometry. Proc. Natl. Acad. Sci. USA105(47), 18126–18131 (2008).
   PubMed Web of Science ®Google Scholar
• Yanagisawa K, Shyr Y, Xu BJ et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet362(9382), 433–439 (2003).
   PubMed Web of Science ®Google Scholar
• Schwartz SA, Weil RJ, Thompson RC et al. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res.65(17), 7674–7681 (2005).
   PubMed Web of Science ®Google Scholar
• Xu BJ, Li J, Beauchamp RD et al. Identification of early intestinal neoplasia protein biomarkers using laser capture microdissection and MALDI MS. Mol. Cell. Proteomics8(5), 936-45 (2009).
   PubMed Web of Science ®Google Scholar
• Albrethsen J. Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin. Chem.53(5), 852–858 (2007).
   PubMed Web of Science ®Google Scholar
• Salzano AM, Paron I, Pines A et al. Differential proteomic analysis of nuclear extracts from thyroid cell lines. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.833(1), 41–50 (2006).
   PubMed Web of Science ®Google Scholar
• Paron I, Scaloni A, Pines A et al. Nuclear localization of Galectin-3 in transformed thyroid cells: a role in transcriptional regulation. Biochem. Biophys. Res. Commun.302(3), 545–553 (2003).
   PubMed Web of Science ®Google Scholar
• Paron I, D’Ambrosio C, Scaloni A et al. A differential proteomic approach to identify proteins associated with thyroid cell transformation. J. Mol. Endocrinol.34(1), 199–207 (2005).
   PubMed Web of Science ®Google Scholar
• Marsee DK, Venkateswaran A, Tao H et al. Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells. J. Biol. Chem.279(42), 43990–43997 (2004).
   PubMed Web of Science ®Google Scholar
• Gorla L, Cantù M, Miccichè F et al. RET oncoproteins induce tyrosine phosphorylation changes of proteins involved in RNA metabolism. Cell Signal.18(12), 2272–2282 (2006).
   PubMed Web of Science ®Google Scholar
• Gorla L, Mondellini P, Cuccuru G et al. Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements. Mol. Carcinog.48(3), 220–231 (2009).
   PubMed Web of Science ®Google Scholar
• Iannetti A, Pacifico F, Acquaviva R et al. The neutrophil gelatinase-associated lipocalin (NGAL), a NF-κB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc. Natl. Acad. Sci. USA105(37), 14058–14063 (2008).
   PubMed Web of Science ®Google Scholar
• Pacifico F, Paolillo M, Chiappetta G et al. RbAp48 is a target of nuclear factor-κB activity in thyroid cancer. J. Clin. Endocrinol. Metab.92(4), 1458–1466 (2007).
   PubMed Web of Science ®Google Scholar
• Ito T, Seyama T, Mizuno T et al. Unique association of p53 mutations with undifferentiated but not differentiated carcinomas of the thyroid gland. Cancer Res.52(5), 1369–1371 (1992).
   PubMed Web of Science ®Google Scholar
• Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pienotti MA. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J. Clin. Invest.91(4), 1753–1760 (1993).
   PubMed Web of Science ®Google Scholar
• Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. High prevalence of mutations of p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest.91(1), 179–184 (1993).
   PubMed Web of Science ®Google Scholar
• Fusco A, Berlingieri MT, Di Fiore PP, Portella G, Grieco M, Vecchio G. One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Mol. Cell. Biol.7(9), 3365–3370 (1987).
   PubMed Web of Science ®Google Scholar
• Friedlander P, Legros Y, Soussi T, Prives C. Regulation of mutant p53 temperature-sensitive DNA binding. J. Biol. Chem.271(41), 25468–25478 (1996).
   PubMed Web of Science ®Google Scholar
• Casamassimi A, Miano MG, Porcellini A et al. p53 genes mutated in the DNA binding site or at a specific COOH-terminal site exert divergent effects on thyroid cell growth and differentiation. Cancer Res.58(13), 2888–2894(1998).
   PubMed Web of Science ®Google Scholar
• Fiscella M, Zambrano N, Ullrich SJ et al. The carboxy-terminal serine 392 phosphorylation site of human p53 is not required for wild-type activities. Oncogene9(11), 3249–3257 (1994).
   PubMed Web of Science ®Google Scholar
• Keller DM, Lu H. p53 serine 392 phosphorylation increases after UV through induction of the assembly of the CK2.hSPT16.SSRP1 complex. J. Biol. Chem.277(51), 50206–50213 (2002).
   PubMed Web of Science ®Google Scholar
• Pines A, Bivi N, Vascotto C et al. Nucleotide receptors stimulation by extracellular ATP controls Hsp90 expression through APE1/Ref-1 in thyroid cancer cells: a novel tumorigenic pathway. J. Cell. Physiol.209(1), 44–55 (2006).
   PubMed Web of Science ®Google Scholar
• Pacifico F, Mauro C, Barone C et al. Oncogenic and anti-apoptotic activity of NF-κB in human thyroid carcinomas. J. Biol. Chem.279(52), 54610–54619 (2004).
   PubMed Web of Science ®Google Scholar
• Qian YW, Wang YC, Hollingsworth Jr RE, Jones D, Ling N, Lee EY. A retinoblastoma-binding protein related to a negative regulator of Ras in yeast. Nature364(6438), 648–652 (1993).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A, Reinberg D. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev.13(15), 1924–1935 (1999).
   PubMed Web of Science ®Google Scholar
• Loyola A, Almouzni G. Histone chaperones, a supporting role in the limelight. Biochim. Biophys. Acta.1677(1–3), 3–11 (2004).
   PubMed Web of Science ®Google Scholar
• Russo D, Bisca A, Celano M et al. Proteomic analysis of human thyroid cell lines reveals reduced nuclear localization of Mn-SOD in poorly differentiated thyroid cancer cells. J. Endocrinol. Invest.28(2), 137–144 (2005).
   PubMed Web of Science ®Google Scholar
• Obermaier C, Jankowski V, Schmutzler C et al. Free-flow isoelectric focusing of proteins remaining in cell fragments following sonication of thyroid carcinoma cells. Electrophoresis26(11), 2109–2116 (2005).
   PubMed Web of Science ®Google Scholar
• Schweppe RE, Klopper JP, Korch C et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J. Clin. Endocrinol. Metab.93(11), 4331–4341 (2008).
   PubMed Web of Science ®Google Scholar
• Berger K, Wissmann D, Ihling C et al. Quantitative proteome analysis in benign thyroid nodular disease using the fluorescent ruthenium II tris(bathophenanthroline disulfonate) stain. Mol. Cell. Endocrinol.227(1–2), 21–30 (2004).
   PubMed Web of Science ®Google Scholar
• Krause K, Schierhorn A, Sinz A et al. Toward the application of proteomics to human thyroid tissue. Thyroid16(11), 1131–1143 (2006).
   PubMed Web of Science ®Google Scholar
• Lin JD, Huang CC, Weng HF, Chen SC, Jeng LB. Comparison of membrane proteins from benign and malignant human thyroid tissues by two-dimensional polyacrylamide gel electrophoresis. J. Chromatogr. B. Biomed. Appl.667(1), 153–160 (1995).
   PubMedGoogle Scholar
• Lin JD, Chan EC, Weng HF, Sheu CA. Two-dimensional electrophoretic analysis of membranous protein from human thyroid tissues and cancer cell lines. Electrophoresis19(18), 3213–3216 (1998).
   PubMed Web of Science ®Google Scholar
• Krause K, Karger S, Schierhorn A, Poncin S, Many MC, Fuhrer D. Proteomic profiling of cold thyroid nodules. Endocrinology148(4), 1754–1763 (2007).
   PubMed Web of Science ®Google Scholar
• Brown LM, Helmke SM, Hunsucker SW et al. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol. Carcinog.45(8), 613–626 (2006).
   PubMed Web of Science ®Google Scholar
• Giusti L, Iacconi P, Ciregia F et al. Fine-needle aspiration of thyroid nodules: proteomic analysis to identify cancer biomarkers. J. Proteome Res.7(9), 4079–4088 (2008).
   PubMed Web of Science ®Google Scholar
• Cortese F, Boffo V, Gargiani M, Servetti S, Argirò G, Casciani CU. Tall cell variant of papillary thyroid cancer. J. Exp. Clin. Cancer Res.17(4), 3–52 (1998).
   PubMed Web of Science ®Google Scholar
• Samuni Y, Gamson J, Samuni A et al. Factors influencing nitroxide reduction and cytotoxicity in vitro. Antioxid. Redox Signal6(3), 587–595 (2004).
   PubMed Web of Science ®Google Scholar
• Fujii J, Ikeda Y. Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein. Redox Rep.7(3), 3–10 (2002).
   PubMed Web of Science ®Google Scholar
• Pham CG, Bubici C, Zazzeroni F et al. Ferritin heavy chain upregulation by NF-κB inhibits TNFα-induced apoptosis by suppressing reactive oxygen species. Cell119(4), 29–42 (2004).
   Google Scholar
• Torres-Cabala C, Panizo-Santos A, Krutzsch HC et al. Differential expression of S100C in thyroid lesions. Int. J. Surg. Pathol.12(2), 107–115 (2004).
   PubMed Web of Science ®Google Scholar
• Torres-Cabala C, Bibbo M, Panizo-Santos A et al. Proteomic identification of new biomarkers and application in thyroid cytology. Acta Cytol.50(5), 518–528 (2006).
   PubMed Web of Science ®Google Scholar
• Srisomsap C, Subhasitanont P, Otto A et al. Detection of cathepsin B up-regulation in neoplastic thyroid tissues by proteomic analysis. Proteomics2(6), 706–712 (2002).
   PubMed Web of Science ®Google Scholar
• Shuja S, Cai J, Iacobuzio-Donahue C et al. Cathepsin B activity and protein levels in thyroid carcinoma, Graves’ disease, and multinodular goiters. Thyroid9(6), 569–577 (1999).
   PubMed Web of Science ®Google Scholar
• Kusunoki T, Nishida S, Nakano T et al. Study on cathepsin B activity in human thyroid tumors. Auris Nasus Larynx22(1), 43–48 (1995).
   PubMedGoogle Scholar
• Franzoni A, Dima M, D’Agostino M et al. Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation. Thyroid19(3), 247–255 (2009).
   PubMed Web of Science ®Google Scholar
• Netea-Maier RT, Hunsucker SW, Hoevenaars BM et al. Discovery and validation of protein abundance differences between follicular thyroid neoplasms. Cancer Res.68(5), 1572–1580 (2008).
   PubMed Web of Science ®Google Scholar
• Suriano R, Lin Y, Ashok BT et al. Pilot study using SELDI-TOF-MS based proteomic profile for the identification of diagnostic biomarkers of thyroid proliferative diseases. J. Proteome Res.5(4), 856–861 (2006).
   PubMed Web of Science ®Google Scholar
• Whelan LC, Power KA, McDowell DT, Kennedy J, Gallagher WM. Applications of SELDI-MS technology in oncology. J. Cell. Mol. Med.12(5A), 1535–1547 (2008).
   PubMed Web of Science ®Google Scholar
• Wang JX, Yu JK, Wang L, Liu QL, Zhang J, Zheng S. Application of serum protein fingerprint in diagnosis of papillary thyroid carcinoma. Proteomics6(19), 5344–5349 (2006).
   PubMed Web of Science ®Google Scholar
• Moretz WH, Gourin CG, Terris DJ et al. Detection of papillary thyroid carcinoma with serum protein profile analysis. Arch. Otolaryngol. Head Neck Surg.134(2), 198–202 (2008).
   PubMedGoogle Scholar
• Diamandis EP. Peptidomics for cancer diagnosis: present and future. J. Proteome Res.5(9), 2079–2082 (2006).
   PubMed Web of Science ®Google Scholar
• Villanueva J, Martorella AJ, Lawlor K et al. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol. Cell. Proteomics5(10), 1840–1852 (2006).
   PubMed Web of Science ®Google Scholar
• Villanueva J, Nazarian A, Lawlor K, Yi SS, Robbins RJ, Tempst P. A sequence-specific exopeptidase activity test (SSEAT) for ‘functional’ biomarker discovery. Mol. Cell. Proteomics7(3), 509–518 (2008).
   PubMed Web of Science ®Google Scholar
• Linkov F, Ferris RL, Yurkovetsky Z et al. Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases. Proteomics Clin. Appl.2(12), 1575–1585 (2008).
   PubMed Web of Science ®Google Scholar
• Pang S, Smith J, Onley D et al. A comparability study of the emerging protein array platforms with established ELISA procedures. J. Immunol. Methods302(1–2), 1–12 (2005).
   PubMed Web of Science ®Google Scholar
• Apel RL, Ezzat S, Bapat BV, Pan N, LiVolsi VA, Asa SL. Clonality of thyroid nodules in sporadic goiter. Diagn. Mol. Pathol.4(2), 113–121 (1995).
   PubMedGoogle Scholar
• Fusco A, Chiappetta G, Hui P et al. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am. J. Pathol.160(6), 2157–2167 (2002).
   PubMed Web of Science ®Google Scholar
• Mustafa D, Kros JM, Luider T. Combining laser capture microdissection and proteomics techniques. Methods Mol. Biol.428, 159–178 (2008).
   PubMedGoogle Scholar